Literature DB >> 30585624

Bronchoalveolar lavage characteristics correlate with HLA tag SNPs in patients with Löfgren's syndrome and other sarcoidosis.

B Karakaya1, M C Schimmelpennink1, L Kocourkova2, J J van der Vis1,3, B Meek4, J C Grutters1,5, M Petrek2,6, C H M van Moorsel1,5.   

Abstract

Genetic susceptibility for sarcoidosis and Löfgren's syndrome (LS) has been associated with prognosis. Human leukocyte antigen (HLA)-DRB1*03 is over-represented in LS, and is associated with a good prognosis, whereas HLA-DRB1*15-positive patients have a more chronic course of sarcoidosis. These HLA-DRB1 types can be easily tagged by single nucleotide polymorphisms (SNPs). Our aim was to evaluate the association between these tag SNPs and bronchoalveolar lavage (BAL) characteristics. In 29 patients, both complete HLA-DRB1* locus genotyping and SNP tagging was performed in parallel. HLA-DRB1 type was inferred from the presence of *03 tag rs2040410 allele A and referred to as *03. HLA-DRB1*15 was inferred from the presence of tag SNP rs3135388 allele A and referred to as *15. For BAL analysis, 122 patients with LS and 165 patients with non-LS sarcoidosis were included. BAL lymphocyte subsets were analyzed by flow cytometry. The presence of tag SNPs completely corresponded with HLA-DRB1*03/*15 genotypes in all 29 patients in whom both HLA-DRB1* genotyping and SNP tagging was performed. In all patients together, *03+ /*15- patients showed a higher CD4+ /CD8+ ratio than *03- /*15+ (P = 0·004) and *03- /*15- (P = 0·001). LS patients with *03+ /*15- had a lower BAL lymphocyte count compared to *03- /*15+  patients (P = 0·011). Non-LS sarcoidosis patients with *03+ /*15- patients showed a decreased CD103+ CD4+ /CD4+ ratio compared to *03- /*15+  patients (P = 0·045) and *03- /*15- patients (P = 0·018). We found that HLA-DRB1*03 and HLA-DRB1*15 can be approximated by genotyping of tag SNPs and corresponds with the degree of lymphocytosis and cell phenotypes in BAL in both LS and non-LS sarcoidosis patients.
© 2018 British Society for Immunology.

Entities:  

Keywords:  MHC; T cells; lung

Mesh:

Substances:

Year:  2019        PMID: 30585624      PMCID: PMC6468184          DOI: 10.1111/cei.13257

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Primary pulmonary sarcoidosis. II. Clinical course and prognosis.

Authors:  S LOFGREN
Journal:  Acta Med Scand       Date:  1953

2.  Diagnostic value of CD103 expression in bronchoalveolar lymphocytes in sarcoidosis.

Authors:  Patrícia Caetano Mota; António Morais; Carmo Palmares; Marília Beltrão; Natália Melo; Ana Cristina Santos; Luís Delgado
Journal:  Respir Med       Date:  2012-04-24       Impact factor: 3.415

3.  High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences.

Authors:  Natalia V Rivera; Marcus Ronninger; Klementy Shchetynsky; Andre Franke; Markus M Nöthen; Joachim Müller-Quernheim; Stefan Schreiber; Indra Adrianto; Bekir Karakaya; Coline H M van Moorsel; Zdenka Navratilova; Vitezslav Kolek; Benjamin A Rybicki; Michael C Iannuzzi; Martin Petrek; Jan C Grutters; Courtney Montgomery; Annegret Fischer; Anders Eklund; Leonid Padyukov; Johan Grunewald
Journal:  Am J Respir Crit Care Med       Date:  2016-05-01       Impact factor: 21.405

Review 4.  Etiology and Immunopathogenesis of Sarcoidosis: Novel Insights.

Authors:  Els Beijer; Marcel Veltkamp; Bob Meek; David Robert Moller
Journal:  Semin Respir Crit Care Med       Date:  2017-07-27       Impact factor: 3.119

5.  Expanded lung T-bet+RORγT+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype.

Authors:  Ylva Kaiser; Rico Lepzien; Susanna Kullberg; Anders Eklund; Anna Smed-Sörensen; Johan Grunewald
Journal:  Eur Respir J       Date:  2016-05-26       Impact factor: 16.671

6.  HLA-B8/DR3 in sarcoidosis. Correlation to acute onset disease with arthritis.

Authors:  E Hedfors; F Lindström
Journal:  Tissue Antigens       Date:  1983-09

7.  Association of HLA B8 with spontaneous resolution in sarcoidosis.

Authors:  M J Smith; C W Turton; D N Mitchell; M Turner-Warwick; L M Morris; S D Lawler
Journal:  Thorax       Date:  1981-04       Impact factor: 9.139

8.  Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients.

Authors:  Johan Grunewald; Anders Eklund; Olle Olerup
Journal:  Am J Respir Crit Care Med       Date:  2003-12-04       Impact factor: 21.405

9.  Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis.

Authors:  R H Winterbauer; J Lammert; M Selland; R Wu; D Corley; S C Springmeyer
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

10.  HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites.

Authors:  Milton D Rossman; Bruce Thompson; Margaret Frederick; Mary Maliarik; Michael C Iannuzzi; Benjamin A Rybicki; Janardan P Pandey; Lee S Newman; Eleni Magira; Bojana Beznik-Cizman; Dimitri Monos
Journal:  Am J Hum Genet       Date:  2003-08-20       Impact factor: 11.025

View more
  3 in total

1.  HLA class II variants defined by next generation sequencing are associated with sarcoidosis in Korean patients.

Authors:  Kateřina Sikorová; Su-Jin Moon; Hee-Young Yoon; Adam Strnad; Jin Woo Song; Martin Petrek
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

2.  Simultaneous testing of immunological sensitization to multiple antigens in sarcoidosis reveals an association with inorganic antigens specifically related to a fibrotic phenotype.

Authors:  E Beijer; R Kraaijvanger; C Roodenburg; J C Grutters; B Meek; M Veltkamp
Journal:  Clin Exp Immunol       Date:  2020-10-06       Impact factor: 4.330

3.  Cytokine gene polymorphisms in Pigeon Breeder's Disease expression.

Authors:  Cláudia Freitas; Bruno Lima; Natália Martins; Natália Melo; Patrícia Mota; Hélder Novais-Bastos; Helena Alves; Oksana Sokhatska; Luís Delgado; António Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-09-30       Impact factor: 0.670

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.